Valuation: TG Therapeutics, Inc.

Market Cap 7.68B 6.86B 6.33B 5.75B 10.76B 730B 10.93B 76.25B 30.17B 382B 28.83B 28.22B 1,205B P/E 2026 *
55.2x
P/E 2027 * 19.1x
Enterprise Value 7.85B 7.01B 6.47B 5.87B 11B 746B 11.17B 77.93B 30.83B 390B 29.46B 28.84B 1,231B EV / Sales 2026 *
8.18x
EV / Sales 2027 * 5.56x
Free-Float
88.56%
Yield 2026 *
-
Yield 2027 * -
1 day+1.90%
1 week+0.37%
Current month-2.89%
1 month-5.82%
3 months-3.34%
6 months+47.92%
Current year+81.72%
1 week 51.83
Extreme 51.8327
55.8
1 month 51.34
Extreme 51.34
57.66
Current year 26.76
Extreme 26.76
59.3
1 year 26.76
Extreme 26.76
59.3
3 years 6.89
Extreme 6.89
59.3
5 years 3.48
Extreme 3.48
59.3
10 years 3.32
Extreme 3.32
59.3
Manager TitleAgeSince
Chief Executive Officer 60 2011-12-28
Director of Finance/CFO 44 2011-12-28
Investor Relations Contact - 2011-11-30
Director TitleAgeSince
Chairman 60 2011-12-28
Director/Board Member 79 2012-02-29
Director/Board Member 62 2012-11-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/10/26 Sell

Director

-5,000 0.0033%
8/7/26 Don

Director

-950 0.0006%
1/28/26 Don

Director

43,197 0.0272%
Change 5-day change 1-year change 3-year change Capi.($)
+1.90%+0.37%+62.50%+631.04% 7.68B
-2.54%+1.31%+54.27%+114.96% 1,135B
-1.42%+3.23%+38.56%+74.44% 636B
+0.16%+0.08%+25.29%+95.23% 505B
-0.31%+3.09%+44.14%+64.80% 378B
-1.34%-0.47%+66.04%+41.00% 358B
-0.68%+2.65%+22.98%+50.39% 295B
-1.20%+3.04%+2.33%+22.86% 266B
-1.79%+1.57%+50.56%+59.08% 237B
-0.73%-0.10%+29.02%+99.67% 193B
Average -0.79%+2.03%+39.57%+125.35% 401.2B
Weighted average by Cap. -1.34%+2.68%+41.06%+80.81%

Financials

2026 *2027 *
Net sales 960M 857M 791M 718M 1.34B 91.17B 1.37B 9.53B 3.77B 47.71B 3.6B 3.53B 151B 1.32B 1.18B 1.09B 986M 1.85B 125B 1.88B 13.09B 5.18B 65.54B 4.95B 4.84B 207B
Net income 162M 145M 133M 121M 227M 15.38B 230M 1.61B 636M 8.05B 608M 595M 25.4B 445M 398M 367M 333M 624M 42.28B 633M 4.42B 1.75B 22.13B 1.67B 1.64B 69.84B
Net Debt 169M 151M 139M 126M 237M 16.04B 240M 1.68B 664M 8.4B 634M 621M 26.5B -348M -311M -287M -260M -487M -33.04B -495M -3.45B -1.37B -17.29B -1.31B -1.28B -54.57B
Projected Income Statement - Annual - TG Therapeutics, Inc.
Logo TG Therapeutics, Inc.
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Employees
399
Date Price Change Volume
26-10-23 US$54.17 +1.90% 1,978,090
26-10-22 US$53.16 -0.08% 1,289,190
26-10-21 US$53.20 -2.44% 1,178,071
26-10-20 US$54.53 +2.31% 1,057,774
26-10-19 US$53.30 -1.24% 1,550,082
Trader
Investor
Global
Quality
ESG MSCI
CCC
MarketScreener Ratings - TG Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
54.17USD
Average target price
69.71USD
Spread / Average Target
+28.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - TG Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. TGTX Stock